Novo Nordisk’s ziltivekimab stumbles again on pair of Phase III terminations
While two trials in heart failure and inflammation will stop early, the ongoing study evaluating ziltivekimab as an acute treatment post-heart failure will continue.
07 September 2026
07 September 2026
While two trials in heart failure and inflammation will stop early, the ongoing study evaluating ziltivekimab as an acute treatment post-heart failure will continue.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.